BIOMEDICAL RESEARCH FORUM LLC – Trademark Portfolio

Entity Type: 16

BIOMEDICAL RESEARCH FORUM LLC holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 4 filings in this category. Currently, 3 trademarks are registered. Notable registered marks include ALZGENE, ALZRISK, and ALZFORUM. The owner is based in Cambridge, MA.

13th Floor

One Main Street

Cambridge, MA 02142

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

ALZFORUM
ALZFORUM
Registered 2013
ALZGENE
ALZGENE
Registered 2005
ALZRISK
ALZRISK
Registered 2005
SWAN
SWAN
Cancelled 2005

Trademark Classifications

BIOMEDICAL RESEARCH FORUM LLC's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (4 filings)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does BIOMEDICAL RESEARCH FORUM LLC have?

BIOMEDICAL RESEARCH FORUM LLC has 4 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 cancelled.

What trademark classes does BIOMEDICAL RESEARCH FORUM LLC file in?

BIOMEDICAL RESEARCH FORUM LLC files trademarks across 1 Nice Classification class. The most active classes are Class 42 (Computer & Scientific). Class 42 covers scientific and technological services; industrial analysis and research services.

What are BIOMEDICAL RESEARCH FORUM LLC's most well-known trademarks?

BIOMEDICAL RESEARCH FORUM LLC's registered trademark portfolio includes well-known marks such as ALZGENE, ALZRISK, and ALZFORUM. These are among 3 currently registered trademarks in the portfolio.

What is BIOMEDICAL RESEARCH FORUM LLC's trademark registration success rate?

BIOMEDICAL RESEARCH FORUM LLC has a 75% trademark registration rate, with 3 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.